Summary. Injections of an opioid agonist (bremazocine) and/or an antagonist (quadazocine) were given to heifers during the luteal or follicular phase of the oestrous cycle. Quadazocine was injected (210 mg/injection) three times at 2-h intervals, and bremazocine was injected (0\m=.\45mg/injection) every 15 min for 6 h. Blood samples were taken every 15 min beginning 6 h before treatments started and continued for 18 h.
Introduction
Considerable progress has been made in the understanding of the hypothalamic control of gonado¬ trophin secretion since Barraclough & Sawyer (1955) observed that morphine inhibited ovulation in the rat. Packman & Rothchild (1976) showed that this effect was reversed by naloxone, and Pert & Snyder (1973) showed that opiate receptors existed in neural tissue. The biological implications of these findings became apparent with the discovery of an endogenous opioid peptide, enkephalin, in the brain (Hughes et al., 1975 ). An opioid control mechanism for LH secretion has been implicated in many reproductive states in a wide spectrum of mammals including rats (Bruni et al, 1977) , chimpanzees (Gosselin et al, 1983) , monkeys (Ferin et al., 1982) , humans (Ropert et al., 1981) , pigs (Barb et al, 1985) and sheep (Schanbacher, 1982; Malven et al, 1984; Brooks et al, 1986c) , but there have been no reports of work carried out during the oestrous cycle in cattle.
Earlier experiments have largely used pharmacological agents such as naloxone and morphine but more recently other compounds have become available. Bremazocine (Sandoz, Basle, Switzerland) is an opiate agonist with a benzomorphan structure and which inhibits LH secretion (Romer et al, 1980; Marko & Romer, 1983) . Quadazocine (Win 44441-3; Sterling Winthrop, Guildford, Surrey, U.K.) is an opioid antagonist with a similar but more potent activity than naloxone and which stimulates LH secretion (Ward et al., 1983; Brooks et al., 1986a 
Treatment and blood samples
Heifers treated during the luteal phase were either controls or treated with quadazocine. The four groups of heifers in the follicular phase were control (C), quadazocine (Q), bremazocine (B) and quadazocine plus bremazocine (QB).
Quadazocine [(2,6 ,11 S*) -(-)-l-cyclopentyl-5-(l,2,3,4,5,6-hexahydro-8-hydroxy-3,6, ll-trimethyl-2,6-methano-3-benzazocin-ll-yl)-3-pentone methanesulphonate)] was dissolved in 5% sterile dextrose (15 mg/ml) and injected (210 mg/injection) 3 times at 2-h intervals. Bremazocine (2-[l-hydroxycyclopropylmethyl]-5-ethyl-9,9-dimethyl-2-hydroxy-6,7-benzomorphan) was dissolved in sterile water (0-15 mg/ml) and injected (0-45 mg/injection) every 15 min for 6 h. All injections were given via indwelling jugular cannulae. Blood samples were taken from the same cannulae at 15-min intervals beginning 6 h before treatments started and continuing for 18 h. Three 6-h sampling periods were designated as control, treatment and after treatment. Daily blood samples were taken via coccygeal vessel puncture for 5 days before treatments started, to monitor blood progesterone concentrations. Oestrous activity was monitored in follicular heifers for 4 days after the treatment period by observing 4 times per day for mounting activity.
Assays and analyses
Plasma from blood samples was stored at -20°C until hormone assays were completed. Assays for LH and progesterone were carried out by the procedures of Webb et al (1977) and the quality control parameters were similar to those published. Pulses or peaks of LH were defined as any sequence of two or more samples that were elevated above the previous baseline or trough with the highest value being at least 50% above this baseline.
Statistical analyses were by analysis of variance (AOV) with the four follicular-phase groups being analysed as a 2x2 factorial to obtain the main effects for quadazocine (Q) and bremazocine (B) treatments as well as their inter¬ action (Q B) (see Steel & Torrie, 1981 
Results

Luteal phase
The plasma progesterone concentrations of one heifer remained below 1 ng/ml during the experimental period, and therefore the data from this animal were excluded from the analysis. The remaining 11 heifers had average progesterone concentrations of 10-9 ± 1-9 ng/ml before and during the experimental period (Fig. 1) . There was no evidence of any effects of the quadazocine injections on LH secretion as estimated by average concentration (21 ±0-15 ng/ml), frequency of peaks (2-8 ± 0-35 peaks/6h) or average peak height (3-4 ± 0-19 ng/ml).
Follicular phase
Average progesterone concentrations for these heifers are shown in Fig. 1 . Concentrations decreased rapidly from 11-5 + 3-3 ng/ml before the injection of cloprostenol and removal of the progesterone coil so that values in all heifers were < 1 ng/ml before the experimental period started. These results plus the fact that there was no evidence of any preovulatory release of LH verify that the experimental period coincided with the follicular phase of the oestrous cycle. Oestrus was observed in all heifers (see Fig. 1 ) at an average interval of 48 + 3-2 h from the start of the exper¬ iment. This interval was not affected (P> 0-2) by any of the treatments.
LH secretion patterns were altered by opioid antagonist and agonist treatments (Fig. 2) . For illustration purposes, LH profiles for representative heifers from each of the four treatment groups (C, Q, B, QB) are shown in Fig. 3 .
Injections of quadazocine increased (P <001) average LH concentrations during the treatment period and the effects of bremazocine were just the opposite with a marked decrease (P <001). However, there was a significant (P < 0-05) interaction between these two treatments due either to the effect of quadazocine being larger when given with bremazocine (QB-B vs Q-C) or the effect of bremazocine being less when given with quadazocine (QB-Q vs B-C). The effect of bremazocine was both more pronounced and more consistent than that of quadazocine. Data for individual heifers showed that 5 of 6 bremazocine-treated heifers had a definite LH response compared to 3 of 6 quadazocine-treated heifers. There was no significant carryover effect of either treatment into the post-treatment period. However LH concentrations over-compensated after quadazocine-treatment but not after brema¬ zocine (Fig. 2) . This difference in response may have been related to the differential magnitude of response to the two drugs during the treatment period.
The increase in LH concentrations due to quadazocine was due to its effect on peak height (P <001) and not peak frequency whereas bremazocine affected both height (P <002) and frequency (P <0-01). This differential effect resulted in the interaction being significant for frequency of peaks (P < 001) but not height. For both the peak number and peak height parameters there were no significant carryover effects into the post-treatment period of either quadazocine or bremazocine. These changes in secretion of LH induced by quadazocine and bremazocine did not change the interval to oestrus (Fig. 1) .
Discussion
The rate of LH secretion during the luteal phase was low relative to that during the follicular phase as has been shown by Rahe et al. (1980) , but this was not reversed by injections of the opioid antagonist, quadazocine. Data reported from other species have shown that LH secretion is increased by opioid antagonists when given during the luteal phase of the oestrous or menstrual cycle or after progesterone injections (Bruni et al., 1977; Quigley & Yen, 1980; Malven et al, 1984; Brooks et al., 1986b, e (Pasternak & Snyder, 1975; Lord et al, 1977; Chang & Cuatrecasas, 1979; Kosterlitz et al, 1981; Pasternak et al., 1981) . However, a mechanism operating via a different population of receptors is not likely since quadazocine binds to at least three opioid receptors (µ, and ; Ward et al., 1983) .
Our interpretation may be incorrect if for example, a higher dose of antagonist is required during the luteal than in the follicular phase. Such a difference has been proposed by Brooks et al., 1986c) . The dose used in this study (0-60 mg/kg) was higher on a bodyweight basis than doses (018 and 0-36 mg/kg) given to sheep and which did produce a response (Brooks et al., 1986a) . The dose of quadazocine used in the present study is roughly equivalent to that of naloxone given to sheep, but naloxone has a lower opioid-antagonist potency than quadazocine (Ward et al, 1983) . The dose was chosen on the basis of the sheep data (Brooks et al, 1986c) . Preliminary data from heifers had indicated that higher doses caused blood haemolysis and minor behavioural changes similar to those observed in sheep (Brooks, 1985) . (Bruni et al, 1977) , human (Quigley & Yen, 1980) , monkey (Ferin et al, 1982) , chimpanzee (Gosselin et al, 1983) and sheep (Brooks et al, 1986c) , which also show agonist and (or) antagonist effects during this stage of the cycle.
An LH response to opiates was not dependent on the presence of progesterone. However, oestradiol may be involved since women in the early follicular phase do not respond to such drugs whereas women in the late follicular phase do (Quigley & Yen, 1980) . However, anoestrous sheep, which do not respond to antagonist treatments, do not become responsive when given oestrogen alone (Brooks et al, 1986b ), a finding which does not support this argument.
The changes in LH secretion induced by quadazocine and bremazocine were not of sufficient magnitude to disturb the follicular maturation process significantly as indicated by normal timing of oestrus after the treatments. Brooks et al (1986c) found that subsequent preovulatory release of LH and luteal activity were impaired when sheep were treated with the opioid agonist DAMME during the follicular phase. In that study, the suppression of LH secretion was much greater and for a longer period than that observed in this study.
In conclusion, these data provide evidence that an opioid-mediated mechanism exists for the control of LH secretion during the follicular phase of the oestrous cycle of heifers. No evidence was found for a similar mechanism during the luteal phase.
